Pediatric committee

Our objectives

The object of the Section is to encourage the organization of international co-operation in pediatric clinical pharmacology and therapeutics by:

Stimulating research in pediatric clinical pharmacology and therapeutics world-wide
Promoting high scientific and ethical standards in clinical medicines research in the pediatric population
Promoting scientific meetings, workshops and courses in pediatric clinical pharmacology and therapeutics in different parts of the world
Improving and harmonising the teaching of pediatric clinical pharmacology and the rational use of medicines in children at both undergraduate and postgraduate levels, particularly in developing countries
Promoting the utilisation of pediatric clinical pharmacological services in health care delivery, particularly in developing countries
Utilising skills of pediatric clinical pharmacology and therapeutics in evaluating patients experiencing adverse drug reactions
Promoting high ethical standards in prescribing and utilisation of medicines in the pediatric population
Encouraging collaboration with other agencies and organisations interested in the study, development and rational use of paediatric medicines, particularly WHO.

Who we are

Chair: Gregory Kearns

Vice-Chair: Facundo Garcia-Bournissen

By-laws of the Pediatric Clinical Pharmacology Section

1) Name

The name of the section is the Pediatric Clinical Pharmacology Section of the International Union of Basic and Clinical Pharmacology (IUPHAR). It is constituted under Section V2 of the statutes of IUPHAR as revised 2006.

2) Aims and functions of the Pediatric Clinical Pharmacology Section

The object of the Section is to encourage the organization of international co-operation in pediatric clinical pharmacology and therapeutics by:

a.  Stimulating research in pediatric clinical pharmacology and therapeutics world-wide
b.  Promoting high scientific and ethical standards in clinical medicines research in the pediatric population
c.  Promoting scientific meetings, workshops and courses in pediatric clinical pharmacology and therapeutics in different parts of the world
d.  Improving and harmonising the teaching of pediatric clinical pharmacology and the rational use of medicines in children at both undergraduate and postgraduate levels, particularly in developing countries
e.  Promoting the utilisation of pediatric clinical pharmacological services in health care delivery, particularly in developing countries
f.  Utilising skills of pediatric clinical pharmacology and therapeutics in evaluating patients experiencing adverse drug reactions
g.  Promoting high ethical standards in prescribing and utilisation of medicines in the pediatric population
h.  Encouraging collaboration with other agencies and organisations interested in the study, development and rational use of paediatric medicines, particularly WHO.

3) Membership

The membership of the Pediatric Clinical Pharmacology Section will comprise of clinical pharmacologists interested in Pediatric Clinical Pharmacology who are members of a national, regional or international society of pharmacology, clinical pharmacology or related discipline that is a member of IUPHAR.

Societies of Pediatric Clinical Pharmacology or Sections of Societies of Pediatric Clinical Pharmacology that are members of IUPHAR may also seek affiliation. Applications for affiliation are to be sent to the Secretary, who shall submit such applications to the Executive Committee for its consideration and approval. Affiliated societies/sections are entitled to nominate one delegate to the business meeting of the Section.

4) Executive Committee

a.  The officers of the Executive Committee(EC) will be elected by majority vote at a properly constituted business meeting of the Section normally held at a World Conference on Clinical Pharmacology and Therapeutics, or at a major world/regional international pediatric clinical pharmacology meeting like the ESDP Biannual Congress.

b.  The Executive Committee shall consist of the Chairman, the Vice-Chairman, the Secretary, the Treasurer, and four additional members. Election shall be from a slate of nominees presented by the Executive Committee. Additional nominations may also be initiated from the floor at the business meetings.

In the event that the office of Chairman becomes vacant between properly constituted business meetings of the Section, the Vice-Chairman shall succeed to that office for the rest of its term. In the event that the offices of Secretary or Treasurer becomes vacant between properly constituted business meetings, the Chairman with the concurrence of the Executive Committee shall appoint one of the Councillors to fill the office for the rest of its term. Under any of the above circumstances or if other positions on the Executive Committee become vacant, the Executive Committee shall be reduced in number until such time as a new Committee is elected.

c.  The Executive Committee may raise and maintain such funds, as it deems necessary to carry out the Section’s activities.

d.  The Executive Committee may establish and determine the membership of Working-Groups concerned with special education or research activities or scientific meetings. The Executive Committee may also discontinue any Working-Group.

e.  Members of the Executive Committee shall be elected for one term of office of four years and may be re-elected for a second term of four years. After completion of two consecutive terms, if not elected to the post of Chairman, Vice-Chairman, Secretary or Treasurer, members of the Executive Committee are not eligible for a third four year term until after an interval of at least four years.

A general business meeting of the Section will normally take place at least every 4 years at each World Conference on Clinical Pharmacology and Therapeutics or at a major world/regional international pediatric clinical pharmacology meeting like the ESDP Congress. The business meeting will receive a report from the Executive Committee and will elect by majority vote of the members and delegates present the next Executive Committee.